Myriad files companion BRCA test in prostate cancer

By staff writers

January 21, 2020 -- Myriad Genetics' BRACAnalysis companion diagnostic for the drug olaparib (Lynparza) is headed for a new indication in prostate cancer, following the filing of a supplemental premarket approval application with the U.S. Food and Drug Administration (FDA).

The test detects and classifies variants of BRCA1 and BRCA2 genes in whole blood specimens. An application for Lynparza, which is a poly (ADP-ribose) polymerase inhibitor marketed by AstraZeneca and Merck, in the second-line treatment of metastatic castration-resistant prostate cancer (mCRPC) with suspected deleterious germline or somatic gene mutations has been accepted by the FDA. The filing has priority review with the agency, and a user fee date has been set for the second quarter.

Both submissions are supported by the pivotal PROfound study of olaparib versus abiraterone (Zytiga, Johnson & Johnson) or enzalutamide (Xtandi, Astellas/Pfizer) in mCRPC. In the study, men with BRCA-mutated disease who were taking Lynparza had significantly longer progression-free survival.

This is just the latest filing to come through in the partnership between Myriad and AstraZeneca. The BRACAnalysis CDx test was approved by the FDA in December as a companion diagnostic to Lynparza for patients with pancreatic cancer. It is also cleared in ovarian cancer and metastatic breast cancer.

Lynparza PARP approval opens door to more pancreatic cancer testing
Approval of the drug olaparib (Lynparza, Merck/AstraZeneca) by the U.S. Food and Drug Administration at the end of 2019 paves the way for more testing...
CVS Health paves way for genetic testing of cancer patients
CVS Health is launching a program that will facilitate genetic testing for cancer patients at the point of prescribing to guide personalized treatment...
BRCA status leads the way in screening men for prostate cancer
Blood testing for levels of prostate-specific antigen gets a bad rap, but a targeted approach is gaining support. A large study published online September...
Myriad to seek further BRACAnalysis CDx FDA approval
Myriad Genetics plans to seek supplementary premarket approval from the U.S. Food and Drug Administration (FDA) for an additional application of its BRACAnalysis...
Foundation Medicine's Lynparza companion test clears FDA
The FoundationOne CDx genomic profiling tumor test is now cleared by the U.S. Food and Drug Administration (FDA) for guiding the use of olaparib (Lynparza)...

Copyright © 2020

Last Updated np 1/21/2020 1:46:35 PM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.